The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
Cancer Cell, 2018/06/11;33(6):1128-1141.e7.
McBride MJ[1], Pulice JL[2], Beird HC[3], Ingram DR[4], D'Avino AR[2], Shern JF[5], Charville GW[6], Hornick JL[7], Nakayama RT[8], Garcia-Rivera EM[2], Araujo DM[9], Wang WL[4], Tsai JW[4], Yeagley M[9], Wagner AJ[10], Futreal PA[3], Khan J[5], Lazar AJ[11], Kadoch C[12]
Affiliations
PMID: 29861296DOI: 10.1016/j.ccell.2018.05.002
Impact factor: 38.585
Abstract
Synovial sarcoma (SS) is defined by the hallmark SS18-SSX fusion oncoprotein, which renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and concomitant loss of BAF47 subunit assembly. Here we demonstrate that SS18-SSX globally hijacks BAF complexes on chromatin to activate an SS transcriptional signature that we define using primary tumors and cell lines. Specifically, SS18-SSX retargets BAF complexes from enhancers to broad polycomb domains to oppose PRC2-mediated repression and activate bivalent genes. Upon suppression of SS18-SSX, reassembly of BAF47 restores enhancer activation, but is not required for proliferative arrest. These results establish a global hijacking mechanism for SS18-SSX on chromatin, and define the distinct contributions of two concurrent BAF complex perturbations.
Keywords: ATP-dependent chromatin remodeling; SWI/SNF (BAF) complexes; bivalency; chromatin; enhancers; fusion oncoprotein; pediatric cancer; polycomb; synovial sarcoma
MeSH terms
Cell Line, Tumor; Chromatin; Enhancer Elements, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Oncogene Proteins, Fusion; SMARCB1 Protein; Sarcoma, Synovial; Exome Sequencing
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download